Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.69 |
| ▸ | EGFR | P00533 | 10/20 | 0.69 |
| ▸ | LCK | P06239 | 9/20 | 0.69 |
| ▸ | ITK | Q08881 | 6/20 | 0.69 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332676 | 1.00 | BTK (0.69) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332677 | 1.00 | BTK (0.69) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332849 | 0.97 | BTK (0.73) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332612 | 0.97 | BTK (0.73) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332611 | 0.97 | BTK (0.73) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332762 | 0.95 | BTK (0.67) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332833 | 0.95 | BTK (0.67) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332763 | 0.95 | BTK (0.67) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL19332751 | 0.89 | BTK (0.62) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL20892847 | 0.89 | BTK (0.62) | BTKEGFRLCKITKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885EGFR 711/4885LCK 6/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885EGFR 711/4885LCK 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.